A randomized, double-blind Phase II study of HMPL-760 plus R-GemOx in relapsed/refractory DLBCL reportedly improved ORR, CRR, PFS, and OS over R-GemOx alone with a manageable safety profile, though no numerical data were disclosed.
HUTCHMED has now opened a registrational Phase III trial in China testing its non-covalent BTK inhibitor HMPL-760 in combination with R-GemOx against placebo plus R-GemOx in transplant-ineligible patients with relapsed or refractory DLBCL after first-line systemic therapy. The study is double-blind, positive-controlled, and plans to enroll approximately 240 patients. Co-primary endpoints are investigator-assessed PFS and OS, with secondary measures including IRC-assessed PFS, response metrics, duration of response, clinical benefit rate, time to response, safety, and pharmacokinetics. The first patient was dosed on March 20, 2026, positioning the program on a registrational track with China’s NMPA.
Strategically, this is a push to secure a first approval for a third-generation, reversible BTK inhibitor in DLBCL in China, where transplant-ineligible patients still frequently cycle through chemoimmunotherapy backbones like R-GemOx. HMPL-760 targets both wild-type and C481S-mutant BTK, a resistance mechanism that limits durability with covalent BTK agents. That differentiation mirrors a global class shift exemplified by non-covalent competitors, but HUTCHMED is aiming at DLBCL—a setting where BTK inhibitors have historically delivered inconsistent benefit unless biologically enriched—rather than the more familiar CLL/MCL territories. Pairing with a pragmatic, widely accessible regimen signals an approval-oriented, operationally straightforward play that could be priced and deployed more easily across Chinese centers than emerging cell therapies or bispecifics. The flip side is a higher evidentiary bar: to change practice against a moving DLBCL salvage landscape that includes CD19-directed modalities and evolving antibody-drug conjugate combinations, the study will likely need clear PFS separation and credible OS signal, not just incremental response gains.
For sites, the design is conventional but operationally dense. Double-blind administration with an oral targeted add-on increases dispensing controls, adherence tracking, and placebo matching. Layering BTK class toxicities onto R-GemOx’s myelosuppression and oxaliplatin neuropathy heightens monitoring and supportive care demands in an older, comorbidity-heavy cohort. PK sampling and IRC-read logistics add data flow and scheduling complexity. If the sponsor introduces stratification or exploratory enrichment for ABC/non-GCB biology or BTK-pathway markers (MYD88/CD79B), labs and central testing could extend screening timelines but may be critical to interpretability. CROs should plan for tight SAE surveillance and cardiology workflows given historical BTK-associated risks, even if non-covalent agents trend cleaner than first-wave covalent inhibitors.
The commercial and regulatory implications hinge on three variables: the magnitude of PFS/OS benefit, subgroup consistency across molecularly heterogeneous DLBCL, and tolerability alongside real-world R-GemOx dosing. Watch for protocol clarity on prior CAR-T or bispecific exposure, stratification factors, and interim analysis triggers that could support a China filing on PFS while OS matures. If the trial reads out positively, HUTCHMED could move quickly to define a salvage niche in China ahead of broader uptake of next-generation immunotherapies, while using the dataset to shape ex-China strategy where standards of care differ. If efficacy concentrates in biologically defined subgroups, a biomarker-led repositioning may follow, with operational consequences for screening and site readiness. Enrollment velocity, safety signals in the first 100 patients, and any early communications on IRC-read concordance will be the near-term indicators to track.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
